Colchicine treatment in COVID-19: the remaining unsolved question
- PMID: 34688436
- PMCID: PMC8530469
- DOI: 10.1016/S2213-2600(21)00462-8
Colchicine treatment in COVID-19: the remaining unsolved question
Conflict of interest statement
AR-V, RP-M, and AG-L are currently researchers in the Impact of Colchicine in Hospitalized Colombian Patients With COVID-19 (COLCOVID19) clinical trial (ClinicalTrials.gov, NCT04539873). AR-V reports fees for conferences from Abbvie, Amgen, Biopas-UCB, Janssen, and Pfizer; and fees for Advisory Board membership from Alexion. All other authors declare no competing interest.
Comment on
-
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet Respir Med. 2021 Dec;9(12):1419-1426. doi: 10.1016/S2213-2600(21)00435-5. Epub 2021 Oct 18. Lancet Respir Med. 2021. PMID: 34672950 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
